Drug Patents owned by Nippon Shinyaku
1. List of Viltepso drug patents
VILTEPSO's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 2024-08-12
Market Authorisation Date: 12 August, 2020
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
VILTEPSO family patents
15
United States
12
Japan
4
European Union
2
Spain
2
Croatia
2
Slovenia
2
Hungary
2
Poland
2
RS
2
Denmark
1
Portugal
1
Russia
1
San Marino
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Lithuania
1
Canada
1
Cyprus
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic